Zelluna ASA Announces New Registered Share Capital Amidst Shareholding Changes

In a significant development for Zelluna ASA, a Norwegian company listed on the Oslo Bors ASA, the company has announced a new registered share capital following a strategic decision by its Board of Directors. This move comes as part of Zelluna’s ongoing efforts to expand its mission of delivering transformative cancer treatments globally. The company’s recent financial maneuvers have caught the attention of investors and industry watchers alike.

On May 27, 2025, Zelluna ASA disclosed the issuance of 227,096 new shares, a decision that was initially announced on May 24, 2025. This issuance was executed against the set-off of an option exercise fee, marking a pivotal moment in the company’s capital structure. The share capital increase has been officially registered with the Norwegian Register of Business Enterprises, elevating Zelluna’s registered share capital to NOK 20,454,162, divided into 20,454,162 shares, each with a par value of NOK 1. Hans Vassgård Eid, the CFO of Zelluna ASA, has been designated as the point of contact for further inquiries regarding this development.

This strategic capital increase is part of Zelluna’s broader mission to pioneer the development of “off the shelf” T cell receptor therapies, aiming to cure advanced solid cancers in a safe and cost-efficient manner. The company’s innovative approach to combining powerful elements of the immune system positions it at the forefront of cancer treatment research and development.

In related news, Zelluna ASA also announced a change in its shareholding structure. Gjelsten Holding AS, a notable shareholder, has seen its ownership interest in Zelluna fall below the 5% threshold, from 5.02% to 4.96% of the share capital. This adjustment, resulting in a total of 1,014,972 shares held by Gjelsten, is attributed to dilution following the private placement of new shares. It’s important to note that this reduction in ownership is not due to any sale of shares by Gjelsten but rather the dilutive effect of the recent capital increase.

These developments underscore Zelluna ASA’s proactive approach to financing its ambitious mission. By increasing its share capital, Zelluna not only secures the necessary resources for its groundbreaking research but also demonstrates its commitment to advancing cancer treatment on a global scale. As the company continues to navigate the complexities of the biotech industry, its strategic financial decisions will undoubtedly play a crucial role in shaping its future trajectory.

For investors and industry observers, Zelluna ASA’s recent activities offer a glimpse into the company’s strategic priorities and its potential to impact the field of cancer treatment significantly. With a focus on innovation and a clear vision for the future, Zelluna ASA is poised to continue its journey towards transforming cancer care worldwide.